☰

William P. Hendricks, Ph.D. - Publications

Affiliations: 
2012 Johns Hopkins University, Baltimore, MD 
Area:
Biomedical Engineering, Molecular Biology
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Sakthikumar S, Warrier M, Whitley D, Facista S, Adkins J, Aman S, Tsinajinnie D, Duran N, Siravegna G, Ahmed Z, Day K, Jenkins B, Patel N, Ryden K, Nadai J, ... ... Hendricks W, et al. Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential. Veterinary and Comparative Oncology. PMID 38053317 DOI: 10.1111/vco.12944  0.312
2020 Ghergurovich JM, O’Shaughnessy J, Levin MK, Killian A, Hendricks W, Espina V, Rabinowitz JD. Abstract P3-02-06: Tracing glucose catabolism in human triple negative breast cancer tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-02-06  0.364
2019 Wang T, Gonzales P, Kotlarczyk K, Lee M, Bossert E, Devore C, Han H, Lang J, Hendricks W, Trent J, Gately S. Abstract LB-058: GB-3103, an epigenetic immunomodulator, shows potent antitumor activity against tumors harboring dual loss of SMARCA4/SMARCA2 ATPases Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-058  0.41
2019 Soldi R, Weston A, Thode T, Lewis R, Kaadige M, Vankayalapati H, Hendricks W, Sharma S. Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) Cancer Research. 79: 3869-3869. DOI: 10.1158/1538-7445.Am2019-3869  0.403
2019 Lorch G, Sivaprakasam K, Zissman V, Perdigones N, Contente-Cuomo T, Nazareno A, Facista S, Wong S, Liang W, Amann JM, Sinicropi-Yao SL, Koenig MJ, Perle KL, Whitsett TG, Murtaza M, ... ... Hendricks WP, et al. Abstract 3705: Identification of frequent HER2 activating mutations in canine primary pulmonary adenocarcinoma Cancer Research. 79: 3705-3705. DOI: 10.1158/1538-7445.Am2019-3705  0.42
2019 Gardner HL, Sivaprakasam K, Briones N, Hendricks W, London CA. Abstract B026: The genomic landscape of canine osteosarcoma implicates DMD as a therapeutic vulnerability Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B026  0.446
2019 Lorch G, Zismann V, Perdigones N, Contente-Cuomo T, Nazareno A, Facista S, Wong S, Liang W, Amann J, Sinicropi-Yao S, Koenig M, Perle KL, Lalani A, Diala I, Eli L, ... ... Hendricks W, et al. P2.14-10 Identification of Frequent, Activating HER2 Mutations and HER2 Inhibitor Response and Resistance in Canine Lung Cancer Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1795  0.33
2018 Kraveka J, Brown V, Ferguson W, Bergendahl G, Roberts W, Foley J, Mitchell D, Oesterheld J, Isakoff M, Neville K, Wada R, Rawwas J, Hanna G, Nagulapally AB, Bond J, ... ... Hendricks W, et al. Abstract CT073: Peds-plan, pediatric precision laboratory advanced neuroblastoma therapy: Molecular guided therapy for high risk neuroblastoma at diagnosis Clinical Trials. 78. DOI: 10.1158/1538-7445.Am2018-Ct073  0.389
2018 Wang Y, Chen SY, Colborne S, Orlando K, Lang J, Karnezis A, Hendricks W, Morin G, Weissman B, Trent J, Huntsman D. Abstract 3673: Targeting the epigenome of small cell hypercalcemic carcinoma of the ovary, hypercalcemic type (SCCOHT) Cancer Research. 78: 3673-3673. DOI: 10.1158/1538-7445.Am2018-3673  0.415
2017 Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, et al. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Research. 27: 524-532. PMID 28373299 DOI: 10.1101/Gr.213348.116  0.35
2017 Lang JD, Hendricks W, Ramos P, Yin H, Sereduk C, Kiefer J, Wang Y, Karnezis AN, Weissman B, Huntsman D, Trent J. Abstract NTOC-090: TARGETING AND EFFICACY OF THE RECEPTOR TYROSINE KINASE INHIBITOR PONATINIB IN SMALL CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE, WORKS THROUGH INHIBITION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-090  0.478
2017 VanSickle E, Zhao P, Mitchell D, Foley J, Steinbrecher J, Rich M, Nagulapally A, Bond J, Hendricks W, Sholler GS. Abstract 4869: The Signature Study: Molecular analysis of pediatric tumors with establishment of tumor models in a biology study Cancer Research. 77: 4869-4869. DOI: 10.1158/1538-7445.Am2017-4869  0.364
2017 Lang JD, Hendricks W, Ramos P, Yin H, Sereduk C, Kiefer J, Wang Y, Karnezis AN, Weissman B, Huntsman D, Trent J. Abstract 1238: Targeting the platelet derived growth factor receptor (PDGFR) with the receptor tyrosine kinase inhibitor ponatinib in small cell carcinoma of the ovary, hypercalcemic type Cancer Research. 77: 1238-1238. DOI: 10.1158/1538-7445.Am2017-1238  0.483
2016 Karnezis AN, Wang Y, Ramos P, Hendricks W, Yin H, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Weissman BE, Trent JM, Gilks CB, Huntsman DG. Abstract A33: Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A33  0.419
2016 Witkowski L, Goudie C, Ramos P, Karnezis AN, Boshari T, Pautier P, Longy M, Knost JA, Saloustros E, McCluggage WG, Hasselblatt M, Hendricks WP, Huntsman D, Levine DA, Trent J, et al. Abstract 3422: The influence of genetic and clinical factors on the outcome following a diagnosis of small cell carcinoma of the ovary, hypercalcemic type Cancer Research. 76: 3422-3422. DOI: 10.1158/1538-7445.Am2016-3422  0.4
2014 Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, et al. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Diseases (Austin, Tex.). 2: e967148. PMID 26942101 DOI: 10.4161/2167549X.2014.967148  0.362
2014 Hendricks WP, Yang J, Sur S, Zhou S. Formulating the magic bullet: barriers to clinical translation of nanoparticle cancer gene therapy. Nanomedicine (London, England). 9: 1121-4. PMID 25118704 DOI: 10.2217/nnm.14.63  0.569
2014 Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genetics. 46: 427-9. PMID 24658001 DOI: 10.1038/Ng.2928  0.327
2014 Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. Plos One. 9: e90028. PMID 24637659 DOI: 10.1371/Journal.Pone.0090028  0.444
2014 Ramos P, Karnezis A, Craig D, Sekulic A, Russell M, Hendricks W, Barrett M, Shumansky K, Yang Y, Shah S, Prentice L, Marra M, Kiefer J, Zismann V, McEachron T, et al. Abstract LB-202: The rare, highly malignant small cell carcinoma of the ovary displays common inactivating germline and somatic mutations in the tumor suppressor SMARCA4 Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-202  0.454
2014 Hendricks WP, Zismann V, Button B, Legendre C, Tembe W, Yin H, Bittner M, Berry D, Huentelman M, Khanna C, LoRusso P, Breen M, Sekulic A, Trent J. Abstract 3417: The genomic landscape of canine melanoma reveals broad mutational heterogeneity and recurrent patterns of structural variation Cancer Research. 74: 3417-3417. DOI: 10.1158/1538-7445.Am2014-3417  0.426
2013 Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, Vogelstein B, Zhou S. A nanoparticle formulation that selectively transfects metastatic tumors in mice Proceedings of the National Academy of Sciences of the United States of America. 110: 14717-14722. PMID 23959886 DOI: 10.1073/Pnas.1313330110  0.564
2010 Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S. PI3Kα inhibitors that inhibit metastasis. Oncotarget. 1: 339-348. PMID 21179398 DOI: 10.18632/Oncotarget.166  0.592
2008 Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. Journal of Neuro-Oncology. 87: 43-50. PMID 18060363 DOI: 10.1007/S11060-007-9498-9  0.318
2007 Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC. Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery. 61: 1048-59; discussion . PMID 18091281 DOI: 10.1227/01.Neu.0000303201.62123.5C  0.355
2004 Pfisterer WK, Hank NC, Preul MC, Hendricks WP, Pueschel J, Coons SW, Scheck AC. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro-Oncology. 6: 290-9. PMID 15494096 DOI: 10.1215/S1152851704000158  0.302
Show low-probability matches.